Q-omics provides the consensus-scored CLUHP4 profile across patient tissues and cancer cell-line models. CLUHP4 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, CLUHP4 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, CLUHP4 RNA expression shows 9,471 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, BRCA, and THYM as cancer lineages where CLUHP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLUHP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLUHP4 survival associations across molecular data types. CLUHP4 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLUHP4 RNA expression–survival associations across cancer types. High CLUHP4 expression shows unfavorable associations in STAD, KIRP, THCA, CHOL and LIHC, but favorable associations in ESCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for CLUHP4 RNA expression.
This table summarizes CLUHP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CLUHP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLUHP4 shows higher tumor expression in BRCA. The BRCA box plot shows higher CLUHP4 RNA expression in tumor versus normal tissue (log2 FC = +0.041, t-test p = .034).
This table shows molecular features associated with CLUHP4 in patient tissues and cancer cell lines. In patient samples, CLUHP4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
